News

Amid rapid market growth, this report offers unique insights into the evolving GLP-1 supply landscape, drawing on QYOBO’s unmatched visibility into global manufacturing sites, regulatory activity, and price trends. It outlines the shift from current Europe-based manufacturing toward increasing reliance on Chinese and Indian suppliers in future supply chains. The report also examines infrastructure investments, API costs, and site-level compliance at GLP-1 manufacturing facilities, providing strategic guidance for decision makers across the pharmaceutical industry.

QYOBO’s first-of-its-kind comparison of API Drug Master Filings across the U.S., Europe, Japan, and China, powered by its unique mapping of 15,000 manufacturing sites worldwide, offers insights into geographic trends and leading players in the global API landscape.

The U.S. government’s 2025 tariff policy marks a major shift by introducing a 20% tariff on pharmaceuticals imported from China, products that were previously exempt under the WTO Pharmaceutical Agreement. Additional tariffs targeting imports from the EU and India are under consideration as of April 2025.
QYOBO is closely tracking these developments. Leveraging data from the QYOBO platform, we analyze the potential implications of the new tariff regime on U.S. pharmaceutical supply security, global supply chain dynamics, and strategic risks and opportunities for pharmaceutical companies.
Tariffs could lead to higher drug prices, supply disruptions, and manufacturing shifts. However, generics manufacturers may face greater challenges adapting due to cost constraints and limited margins.

Private equity investments are transforming the pharmaceutical manufacturing sector, unlocking new opportunities amid shifting global market dynamics. With over 1,900 manufacturing sites across Europe, strategic acquisitions require data-driven insights to navigate compliance risks, ownership complexities, and supply chain dependencies. Discover how advanced analytics platforms empower investors to make informed M&A decisions and gain a competitive edge in this evolving landscape.

The U.S. government’s 2025 tariff policy marks a major shift by introducing a 20% tariff on pharmaceuticals imported from China, products that were previously exempt under the WTO Pharmaceutical Agreement. Additional tariffs targeting imports from the EU and India are under consideration as of April 2025.
QYOBO is closely tracking these developments. Leveraging data from the QYOBO platform, we analyze the potential implications of the new tariff regime on U.S. pharmaceutical supply security, global supply chain dynamics, and strategic risks and opportunities for pharmaceutical companies.
Tariffs could lead to higher drug prices, supply disruptions, and manufacturing shifts. However, generics manufacturers may face greater challenges adapting due to cost constraints and limited margins.

Amid ongoing shifts in the global pharmaceutical market — including increasing regulatory scrutiny, raw material shortages, and evolving geopolitical tensions — the industry continues to navigate a landscape of uncertainty. In 2024, global API prices have largely trended downward, with QYOBO’s platform tracking these changes for thousands of APIs, excipients, intermediates and chemicals. This analysis describes API price fluctuations, highlights shifts across therapeutic categories, and provides AI-driven price forecasts for the coming months.